Meanwhile, the MEDIOLA trial showed that a combination of PARPi and anti-PD-L1 led to enhanced antitumor activity in one of the four cohorts for patients with advanced-stage BRCA1/2-mutant breast cancers [122]. This evidence concerns the gene CD274 and breast carcinoma.